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Abstract
Aims Patients with heart failure (HF) are known to have a reduced pulmonary diffusion capacity for carbon monoxide (DLCO),
but little is known about how lung function relates to central haemodynamics. The aim of this study was to investigate the
association between haemodynamic variables and pulmonary diffusion capacity adjusted for alveolar volume in congestive
HF patients and to analyse how predicted DLCO/VA affects mortality in relation to the haemodynamic status.
Methods and results We retrospectively studied right heart catheterization (RHC) and lung function data on 262 HF patients
(mean age 51 ± 13 years) with a left ventricular ejection fraction < 45% referred non-urgently for evaluation for heart trans-
plantation (HTX) or left ventricular assist device (LVAD). Univariate and multivariate linear regression models were constructed
to examine the associations between predicted values of DLCO/VA, forced vital capacity (FVC) and forced expiratory volume in
1 s (FEV1), and haemodynamic parameters [pulmonary capillary wedge pressure (PCWP), central venous pressure, cardiac in-
dex, mean pulmonary artery pressure, and mean arterial pressure] as well as other factors known to affect lung function in HF.
FEV1 was reduced to <80% of predicted value in 55% of the population, and DLCO/VA was reduced in 63% of the population.
DLCO/VA correlated positively with pulmonary capillary wedge pressure in both univariate and multivariate analyses for all
included patients (P < 0.001 and P = 0.045, respectively) and a restricted population of patients with the shortest time be-
tween RHC and lung function testing (P = 0.005, P = 0.015). DLCO/VA predicted mortality in multivariate models [hazard ratio
1.5 (1.1–2.1)] but not the combined endpoint of death, LVAD implantation, or HTX. There was no signiﬁcant correlation
between haemodynamics and predicted FVC or FEV1.
Conclusions Pulmonary diffusion capacity correlates positively with left ventricular ﬁllings pressures, and reduced values pre-
dict increased mortality in patients with HF. This might be driven by increased lung capillary volume in patients with pulmonary
congestion.
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Introduction
Heart failure (HF) is frequently associated with functional and
structural changes in the lungs. Indeed, lung function abnor-
malities such as impaired respiratory mechanics and gas
exchange can be attributed to HF in the absence of respira-
tory diseases.1,2 However, pulmonary co-morbidities also fre-
quently co-exist with HF, and chronic obstructive pulmonary
disease (COPD) is a common ﬁnding in the HF population.3
The co-existence of COPD and HF is often a therapeutic and
diagnostic challenge in HF management,4 and COPD in
patients with HF is associated with a worse clinical status
and an increased risk of cardiovascular death and hospitaliza-
tions.5 HF-related changes in pulmonary function are likely
multifactorial and explained by interstitial and/or alveolar
oedema, increased heart size leading to lung tissue displace-
ment, pulmonary vascular remodelling, and respiratory
muscle weakness.6–9 It is well known that patients with con-
gestive HF (CHF) have a reduction in pulmonary diffusion ca-
pacity for carbon monoxide (DLCO),
1 and CHF is known to
increase the resistance to gas transfer across the alveolar–
capillary membrane.10 Some studies have shown that a
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reduced diffusion capacity contributes to exercise intoler-
ance11 and is a predictor of mortality in HF patients.12 The
mechanism behind these ﬁndings, however, is unresolved. It
is clear that cardiopulmonary interaction is an important ele-
ment in HF pathophysiology. Little is known about the associ-
ation between central haemodynamics and pulmonary
diffusion capacity in CHF, and the intention of this article
was to investigate the role of haemodynamics in the interac-
tion between heart and lungs. Limited data are available, and
the importance of haemodynamic status, particularly pulmo-
nary artery and left ventricular ﬁlling pressures for diffusion
capacity in advanced HF, is not clear. Nor is it known if an as-
sociation between DLCO and outcome is driven by haemody-
namic abnormalities in these patients. The aim of this study
was to investigate the association between haemodynamic
variables and pulmonary diffusion capacity adjusted for alve-
olar volume in CHF patients and to analyse how predicted
DLCO/VA affects mortality in relation to the haemodynamic
status.
Methods
Patients and study design
This is a retrospective study of HF patients who underwent
right heart catheterization (RHC) at the Department of
Cardiology at Copenhagen University Hospital, Rigshospitalet,
between January 2002 and February 2016. Patients were
referred for evaluation for heart transplantation (HTX) or im-
plantation of a left ventricular assist device (LVAD), and opti-
mal medical therapy was instituted before referral. Both
hospitalized patients (not in an intensive care unit) and
outpatients with advanced CHF were included in this study.
If a patient had more than one RHC in the time period, only
data from the ﬁrst catheterization were used. Inclusion
criteria were HF with documented left ventricular ejection
fraction (LVEF) less than 45% and a record of pulmonary func-
tion tests (PFTs) within 3 months of the RHC. Patients previ-
ously treated with LVAD or HTX were excluded from the
study. Patients were not required to have symptoms of ad-
vanced HF at the time of referral, implying that some patients
could be characterized as New York Heart Association (NYHA)
Class 2 at the time of RHC. These patients were included as
they had recently experienced advanced HF symptoms or
their HF condition was considered serious enough to justify
referral for investigation including undergoing an invasive car-
diac catheterization. Patients were identiﬁed in the hospitals’
cardiac catheterization database, and data were extracted
from this database, as well as from patient medical records
and the departments’ echocardiography database. The
research protocol was approved by the Danish Medical
Agency (3-3013-1365/1) and the Data Protection Agency
(RH 2015-153). Individual patient consent was not required
owing to the retrospective nature of the study.
Haemodynamic evaluation
Right heart catheterization was performed using a Swan–
Ganz catheter by four different experienced physicians. All
studies were performed in the cardiac catheterization labora-
tory after appropriate zeroing and calibration of the pressure
transducer. The catheter was inserted in the internal jugular
or the femoral vein, and the correct placement of the
Swan–Ganz catheter was evaluated by ﬂuoroscopy and by
visualization of pressure curves on a monitor.
Patients underwent RHC with determination of pulmonary
capillary wedge pressure (PCWP), pulmonary artery systolic
pressure and pulmonary artery diastolic pressure (PADP),
mean pulmonary artery pressure (MPAP), central venous
pressure (CVP), cardiac output (CO), cardiac index (CI), and
mean arterial pressure (MAP). CI was determined as CO di-
vided by the body surface area (BSA). CO was measured by
the thermodilution technique. BSA was determined using
the DuBois method. MAP was estimated using the formula
MAP = [(2 × diastolic blood pressure) + systolic blood pres-
sure]/3. Pulmonary vascular resistance (PVR) in Wood units
was calculated as PVR = (MPAP  PCWP)/CO. The diastolic
pressure gradient (DPG) was calculated as PADP  PCWP,
and a DPG ≥ 7 was considered to indicate pulmonary vascular
remodelling.13
Pulmonary function tests
To be included in this study, HF patients were required to
have documented PFTs performed within 3 months of the
RHC. PFTs included spirometry and diffusion capacity. The
spirometry was repeated until (at least) three successful
and reproducible results were obtained, and it was reported
as the highest values achieved.
Diffusion capacity was measured using single-breath CO
technique. Two independent diffusion capacity measure-
ments were performed with a minimum of 4 min intervals.
If the results varied <10%, the ﬁnal result was given as the
average value. If the variation was >10%, a third measure-
ment was made and the average of the three measurements
was used. All lung function tests were performed in a
dedicated laboratory at Rigshospitalet at the Department of
Clinical Physiology and Nuclear Medicine. Unless otherwise
indicated, lung function variables are expressed as per cent
of predicted values14,15; e.g. per cent forced expiratory
volume in 1 second (%FEV1) denotes measured FEV1 divided
by expected FEV1 multiplied by 100.
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Statistical analysis
Categorical variables are reported as numbers (n) and
percentages (%). Continuous variables are reported as
mean ± standard deviation (SD), unless indicated otherwise.
We constructed univariate linear regression analyses to exam-
ine the associations between FEV1, forced vital capacity (FVC),
DLCO/VA, and the haemodynamic parameters (PCWP, MPAP,
CVP, CI, MAP, PVR, and DPG). Signiﬁcant variables were in-
cluded in multivariable models along with other factors
known to affect lung function in HF patients (COPD, diabetes
mellitus, and smoking). Two-sided P values were used; a P-
value< 0.05 was considered statistically signiﬁcant. Statistical
analyses were performed using SPSS (Version 25, IBM Corp.).
Follow-up date was set to 1 February 2016. Events were
deﬁned as patients being alive at follow-up date, undergoing
LVAD implantation or HTX, or dead. Implantation of an LVAD
was used as bridge to transplantation or destination therapy.
Kaplan–Meier survival curve was plotted, and Cox propor-
tional hazards models were used to estimate hazard ratios
with 95% conﬁdence intervals. Patients were divided into
three groups according to tertiles of %FEV1, %FVC, and
%DLCO/VA. Cox regression analyses were performed to
identify predictors of death (censoring patients at time of
LVAD or HTX) or predictors of the combined endpoint of
death, LVAD implantation, or HTX.
Results
Baseline characteristics
A total of 519 patients with LVEF < 45% underwent RHC in
the study period, but 257 were excluded owing to missing
PFTs within the allowed time frame. Hence, a total of 262
subjects formed the study population. Their characteristics
are listed in Table 1. The mean age was 51 years; most
were men (78%) and mildly overweight (body mass in-
dex = 26.4 kg/m2). The vast majority (91%) had a severely re-
duced LVEF ≤ 25%, and 64% were in NYHA Class 3 or 4 at the
time of examination. One or more clinical signs of congestion
such as elevated jugular pressure and peripheral oedema
were present in 49% at the time of examination. While 19%
were active smokers, the majority were previous smokers
(53%). Only 8% were diagnosed with COPD. Most patients
were treated with recommended HF medications, although
only 68% tolerated beta-blocker. Only 5% of patients were
treated with inotropes at the time of RHC, and none were
receiving mechanical circulatory support (as this was an
exclusion criterion). Bronchodilators for COPD or asthma
were used by 3% of the population.
Percentage FEV1 was abnormally low (<80%) in 55% of the
population, and mean %DLCO/VA was reduced (63%).
Haemodynamics are presented in Table 1. Patients had signs
of increased ﬁlling pressures and depressed CO.
Association between haemodynamic variables
and lung function parameters
Mean time between PFTs and RHC was 7 days. To test for a
potential inﬂuence of time elapsed from RHC to pulmonary
function testing, sensitivity analyses were performed re-
stricted to the population to those with a maximum of 2 days
between the two measurements. Univariate and multivariate
linear regression models are shown in Table 2. With the use
of univariate analysis, a signiﬁcant, positive association be-
tween %DLCO/VA and PCWP (r
2 = 0.051, P = 0.005) was found
(Figure 1). Further, %DLCO/VA and MPAP were associated
(r2 = 0.029, P = 0.036). There were no signiﬁcant associations
between %DLCO/VA and CI, MAP, DPG, PVR, or CVP.
When multivariate analyses were performed including the
variables PCWP, MPAP, history of smoking, diabetes mellitus,
and COPD, PCWP remained signiﬁcantly associated with
%DLCO/VA (P = 0.015).
Analyses were repeated including all 262 patients, and
there was still a signiﬁcant correlation between %DLCO/VA
and PCWP in both univariate (r2 = 0.048, P ≤ 0.001) and
multivariate analyses (P = 0.045) with similar coefﬁcients
compared with those of the restricted population.
Pulmonary vascular resistance was signiﬁcantly correlated
with %FVC (r2 = 0.016, P = 0.047) and %FEV1 (r
2 = 0.022,
P = 0.018) but not with %DLCO/VA for all patients included.
Smoking and chronic obstructive pulmonary
disease
Active smokers had a reduced %FEV1 (72% vs. 82%), %FVC
(79% vs. 84%), and %DLCO/VA (77% vs. 92%) than had non-
smokers. There was also a signiﬁcant correlation between
%DLCO/VA and PCWP in this subpopulation (r
2 = 0.103,
P = 0.03). There were no signiﬁcant changes in our results
when patients diagnosed with COPD were excluded from
the analysis.
The use of bronchodilators or beta-blockers was not signif-
icantly correlated to any of the lung function parameters.
Lung function parameters, haemodynamics, and
outcome
Mean follow-up time was 3.3 years. At the end of follow-up,
83 patients (32%) had died and 179 were alive (68%). Out of
262 patients, 37 (14%) received an LVAD and 78 (30%) were
transplanted. While 68 (38%) were alive with an LVAD or
transplant at follow-up, 111 (62%) were alive without.
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Table 1 Baseline characteristics
Total
n = 262
n
Age (years) 262 51 ± 13
Gender (male) 262 204 (78%)
Body mass index (kg/m2) 259 26.4 ± 5
NYHA 3 or 4 247 158 (64%)
LVEF ≤ 25% 262 237 (91%)
Ischaemic aetiology 262 85 (33%)
Risk factors
Smokinga 252 181 (71.8%)
Alcoholb 262 19 (7.3%)
Medical history
COPD 260 20 (7.7%)
Diabetes mellitusc 262 45 (17.3%)
Clinical signs
Pleural effusion 71 20 (28.2%)
Pulmonary rales 250 38 (15.2%)
JVP 185 47 (25.4%)
Peripheral oedema 237 67 (28.3%)
Ascites 71 20 (28.2%)
Hepatomegaly 154 34 (22.1%)
S3 gallop 194 234 (17.5%)
NT-pro-BNP (ng/L) 86 3826 ± 4172
Device therapy
ICD 262 46 (17.6%)
CRT-D 262 39 (14.9%)
CRT-P 262 11 (4.2%)
Pacemaker 262 5 (1.9%)
None 262 161 (61.5%)
Medication
ACE inhibitors or angiotensin II receptor blockers 262 201 (76.7%)
Beta-blockers 262 179 (68.3%)
Aldosterone receptor antagonists 262 174 (66.4%)
Loop diuretics 262 236 (90.1%)
Inotropic support 262 14 (5.3%)
Resting haemodynamic parameters
Heart rate (b.p.m.) 190 81 ± 18
Systolic blood pressure (SBP) (mmHg) 196 104 ± 18
Diastolic blood pressure (DBP) (mmHg) 195 65 ± 11
Mean arterial pressure (MAP) (mmHg) 195 78 ± 12
Central venous pressure (CVP) (mmHg) 256 10.9 ± 6.8
Cardiac index (CI) (L/min/m2) 253 2.4 ± 0.7
Pulmonary capillary wedge pressure (PCWP) (mmHg) 259 20.5 ± 8.4
Mean pulmonary artery pressure (MPAP) (mmHg) 257 28.6 ± 9.9
Pulmonary artery systolic pressure (PASP) (mmHg) 259 42.8 ± 14.5
Pulmonary artery diastolic pressure (PADP) (mmHg) 257 21.5 ± 8.1
Systemic vascular resistance (SVR) (dynes·s/cm5) 191 1250 ± 457
Pulmonary vascular resistance (PVR) (dynes·s/cm5) 253 153 ± 115
Diastolic pressure gradient (DPG) 257 1.0 ± 4.1
Pulmonary function tests
Forced vital capacity (FVC) (L) 262 3.5 ± 1.0
Forced vital capacity (FVC) (% of predicted) 257 81.9 ± 18.9
Forced expiratory volume in 1 s (FEV1) (L) 262 2.7 ± 0.8
Forced expiratory volume in 1 s (FEV1) (% of predicted) 262 77.3 ± 19.8
FEV1/FVC (% of predicted) 262 76.4 ± 9.0
Pulmonary diffusion capacity for carbon monoxide (DLCO) (mmol/min/kPa) 259 6.3 ± 1.7
Pulmonary diffusion capacity for carbon monoxide (DLCO) (% of predicted) 258 62.6 ± 15.9
Alveolar volume adjusted pulmonary diffusion capacity for carbon monoxide (DLCO/VA) 257 1.3 ± 0.3
Alveolar volume adjusted pulmonary diffusion capacity for carbon monoxide (DLCO/VA) (% of predicted) 254 84.1 ± 18.1
n deﬁnes the number of patients with obtained information in the category. Values are given as numbers and proportions [n (%)] or
means with standard deviations (SDs).
ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; CRT-D, cardiac resynchronization therapy deﬁbrilla-
tor; CRT-P, cardiac resynchronization therapy pacemaker; ICD, implantable cardioverter deﬁbrillator; JVP, jugular venous pressure; LVEF,
left ventricular ejection fraction; NYHA, New York Heart Association; NT-pro-BNP, N-terminal pro-BNP.
aCurrent or former.
b>14/21 units/week.
cNon-insulin-dependent diabetes mellitus or insulin-dependent diabetes mellitus.
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The results of the univariate and multivariate Cox regres-
sion models are presented in Table 3. In a univariate analysis,
patients in the lower tertiles of %FEV1 and %FVC had a 30%
and 40% increased risk of death, LVAD, or transplantation
than had those in the highest tertiles (both, P < 0.05). In
multivariate Cox models adjusted for age and gender, neither
%FEV1 nor %FVC remained signiﬁcant predictors of the
combined endpoint.
Multivariate Cox analysis identiﬁed %DLCO/VA as a predic-
tor of mortality with a 50% increased risk when comparing
lower tertiles with highest tertiles (P < 0.05), but it was not
a signiﬁcant predictor of the combined endpoint. Kaplan–
Meier survival curves are presented in Figure 2. There was
no statistical signiﬁcant interaction between PCWP and
%DLCO/VA.
Discussion
The main ﬁndings of the present study are that pulmonary
diffusion capacity adjusted for alveolar volume correlated
Table 2 Association between %DLCO/VA and haemodynamic variables
Variables
Total (n = 262) Within 2 days (n = 156)
P-value r2 β P-value r2 β
Univariate analysis
PCWP <0.001 0.048 0.219 0.005 0.051 0.226
CI NS NS
CVP NS NS
MAP NS NS
MPAP 0.003 0.036 0.190 0.036 0.029 0.170
DPG NS NS
PVR NS NS
Multivariate analysis
0.139 0.18
PCWP 0.045 0.252 0.015 0.388
COPD 0.047 0.122 0.034 0.165
Smokinga <0.001 0.254 <0.001 0.283
Diabetes mellitus NS NS
MPAP NS NS
%DCLO/VA, percentage of predicted value of pulmonary diffusion capacity adjusted for alveolar volume; CI, cardiac index; COPD, chronic
obstructive pulmonary disease; DPG, diastolic pressure gradient; MAP, mean arterial pressure; MPAP, mean pulmonary artery pressure;
PCWP, pulmonary capillary wedge pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance.
aCurrent or former.
Figure 1 Association between %DLCO/VA and PCWP. PFTs within 2 days of RHC (n = 156). %DCLO/VA, percentage of predicted value of pulmonary dif-
fusion capacity adjusted for alveolar volume; PFTs, pulmonary function tests; PCWP, pulmonary capillary wedge pressure; RHC, right heart
catheterization.
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positively, albeit modestly, with left ventricular ﬁlling pres-
sures while dynamic lung parameters (%FEV1 and %FVC) did
not correlate with haemodynamics in advanced HF. Further,
%FEV1 and %FVC predicted adverse outcome, although this
association was not apparent after adjustment for confound-
ing factors, whereas diffusion capacity predicted mortality
when adjusting for confounders.
Pulmonary diffusion capacity for carbon monoxide (DLCO) is
reduced in HF,1,2,7,10,16,17 which was also conﬁrmed in the
current study when compared with the applied reference
material.
Only limited data have been published on the
association between central haemodynamics and pulmonary
diffusion capacity in CHF. In this study, PCWP was the only
Table 3 Hazard ratios in Cox regression models
Model 1
(combined endpoint)
Model 2
(combined endpoint)
Model 3
(combined endpoint)
Model 4
(all-cause mortality)
%FEV1 1.30* (1.10–1.52) 0.94 (0.67–1.32) 0.93 (0.65–1.33) 1.15 (0.69–1.91)
%FVC 1.40* (1.11–1.64) 1.24 (0.87–1.73) 1.27 (0.89–1.80) 1.35 (0.82–2.22)
%DLCO/VA 0.99 (0.81–1.21) 1.22 (0.97–1.53) 1.22 (0.97–1.52) 1.53* (1.11-2.11)
PCWP 1.03 (0.99–1.07) 1.03 (1.00–1.08) 1.03 (0.98–1.07)
CI 0.64* (0.48–0.86) 0.60** (0.45–0.81) 0.59* (0.38-0.90)
MPAP 1.01 (0.98–1.05) 1.01 (0.98–1.04) 1.03 (0.99–1.07)
CVP 1.00 (0.97–1.03) 0.99 (0.97–1.03) 0.97 (0.92–1.03)
Age 1.08* (1.02–1.04) 1.05** (1.05–1.08)
Gender (male) 1.09 (0.68–1.73) 4.50** (1.72–11.77)
Model 1–3: Data are given as hazard ratio (HR) of combined endpoint of death, heart transplantation, or LVAD implantation with 95%
conﬁdence interval. Model 4: Data are given as HR of all-cause mortality with 95% conﬁdence interval.
Model 1: Univariate models for lung function parameters in tertiles. Model 2: Multivariate model for lung function parameters in tertiles
and haemodynamics. Model 3: Multivariate model for lung function parameters in tertiles and haemodynamics adjusted for age and gen-
der. Model 4: Multivariate model for lung function parameters in tertiles and haemodynamics adjusted for age and gender. Hazard ratios
are given per 10 units of increase.
%DLCO/VA, percentage of predicted value of pulmonary diffusion capacity adjusted for alveolar volume; %FEV1, percentage of predicted
value of forced expiratory volume in 1 s; %FVC, percentage of predicted value of forced vital capacity; CI, cardiac index; CVP, central ve-
nous pressure; MPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure.
*P < 0.05.
**P < 0.001.
Figure 2 Kaplan–Maier curve. Blue = highest tertile of %DLCO/VA. Red = intermediate tertile of %DLCO/VA. Green = lowest tertile of %DLCO/VA. %DCLO/
VA, percentage of predicted value of pulmonary diffusion capacity adjusted for alveolar volume.
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haemodynamic variable associated with %DLCO/VA in univari-
ate and multivariate analyses, and, interestingly, there was a
positive association between predicted diffusion capacity
adjusted for alveolar volume and PCWP. Alteration in DLCO
depends on changes in its two components, the alveolar–
capillary membrane resistance (DM) and the amount of blood
volume available for gas exchange (VC).
The two components modify DLCO in opposite ways, where
DM decreases and VC increases DLCO.
17,18 PCWP is an indirect
estimate of left atrial pressure and the left ventricular
end-diastolic pressure (LVEDP). Increases in LVEDP are
transmitted back to the pulmonary capillaries. As pulmonary
congestion usually increases capillary blood volume,1,18 it
could theoretically explain the positive association between
PCWP and DLCO/VA. Further studies are of course necessary
to verify this hypothesis.
It is well established that lung volume is reduced in HF
patients; and the importance of alveolar volume (VA), i.e.
the volume of air in the lung available for gas exchange, in
interpreting diffusion capacity is, therefore, not without sig-
niﬁcance. In addition, VA, furthermore, bears a prognostic
value because reduced VA is also found to be a signiﬁcant,
independent predictor of mortality in patients with
systolic HF.19
Wright et al.7 studied 132 patients with severe chronic CHF
referred for HTX and found no association between PCWP
and DLCO. Compared with patients in the present study, their
population did, in general, have a higher PCWP (26 vs.
20.5 mmHg in the present study) and a slightly higher DLCO
(64.5 vs. 62.6%). Also, they did not specify time between
RHC and PFTs.
In a study of HF patients, Puri et al.17 reported that a lower
DLCO was associated with more severe HF and found that the
main component of the impaired diffusion capacity is related
to the membrane component (DM). Fluid accumulation is a
classic clinical feature in HF, and patients with lung conges-
tion have been shown to display a greater reduction in
DLCO.
19 A reversible reduction in membrane diffusion capacity
can be observed by infusion of saline into CHF patients,20,21
suggesting that, to some extent, there is a variable compo-
nent in diffusion capacity seen in CHF, which could be
targeted for therapeutic intervention. However, several of
studies of patients after HTX have shown that while HTX
has a positive effect on total lung capacity, FEV1 and FVC, it
does not improve DLCO or DLCO/VA at long-term follow-
up.22,23 This suggests that chronic irreversible changes that
leads to permanently reduced diffusion capacity despite
improved haemodynamics may occur as a consequence of
remodelling.
Reduction in diffusion capacity is important in CHF as
inability of the alveolar–capillary membrane to maintain an
effective gas diffusion contributes to exercise intolerance in
CHF.11 However, the importance of DLCO may extend beyond
that as studies of both HF patients with reduced ejection
fraction12 and preserved ejection fraction24 have reported a
signiﬁcantly worse outcome and higher mortality rate in HF
patients with lower diffusion capacity. Olson et al.12 studied
134 HF patients without co-morbidities that could inﬂuence
pulmonary function and examined the utility of resting pul-
monary function measures in predicting event-free survival
in patients with HF. FEV1 and FVC demonstrated the stron-
gest relationship with event-free survival, but DLCO and VA
were also found to be important prognostic markers. In our
study, %DLCO/VA was a signiﬁcant prognostic predictor of
mortality but did not predict the combined endpoint of
death, LVAD, or transplantation, while %FEV1 and %FVC were
predictors for the combined endpoint in univariate Cox anal-
ysis but did not remain signiﬁcant in multivariate models. One
reason for this discrepancy could be differences in patient se-
lection and the endpoints for the study, as fewer patients
were transplanted and LVAD implantation was not included
in the Olsen study. There is growing evidence suggesting that
pulmonary function testing could provide useful additional
information in most patients with CHF with or without respi-
ratory co-morbidities in relation to daily management and as
a predictor of mortalily.16,25
There were no signiﬁcant changes in our results when pa-
tients diagnosed with COPD were excluded from all of our
analysis; hence, we decided not to exclude them from the
study.
Clinical implication
The heart and lungs are anatomically connected, but our
knowledge as to how haemodynamics are related to lung
function is sparse. We investigated this relationship and
found a positive correlation between diffusion capacity and
PCWP, which could be explained by an increase in blood
volume available for gas exchange, a consequence of pulmo-
nary congestion. This information is of importance when
interpreting PFTs in patients worked up for HTX of LVAD. As
we have shown that diffusion capacity is related to mortality,
the data should spike further research aimed at clarifying the
pathophysiology in lung diffusion capacity in HF and leading
to a better understanding of the mechanisms of the lung–
heart interactions.
Study limitations
Owing to the limitations of a cross-sectional study, we cannot
conclude on any cause–effect relationship between PCWP
and diffusion capacity, and furthermore, because the data
collection was limited to one time point, it may not be repre-
sentative of the entire trajectory of HF patients. In our study
population, only 7% of the patients were diagnosed with
COPD, which is signiﬁcantly less than in the general
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population. This is probably because clinicians are more reluc-
tant to refer patients with (severe) COPD to evaluation for
HTX and/or LVAD, and thus, there is most likely selection bias
at the referral level.
We investigated a selected HF population with a mean age
of 51, which is considerably younger than average HF pa-
tients, which may limit the generalizability to the general HF
population.
In addition, our study did not allow us to distinguish
between the vascular and membrane components of DLCO.
Conclusions
This study explored the association between haemodynamic
variables and lung function parameters in patients with
CHF. This study is the ﬁrst to demonstrate a positive associa-
tion between DLCO/VA and PCWP, possibly explained by an
increase in blood volume available for gas exchange, a
consequence of pulmonary congestion. DLCO/VA predicted
mortality but not the combined endpoint of death, LVAD im-
plantation, and HTX. Further studies allowing for distinction
between the vascular and membrane components of DLCO
are necessary to explore this association between diffusion
capacity and PCWP.
Conﬂict of interest
None declared.
Funding
None declared.
References
1. Guazzi M. Alveolar gas diffusion abnor-
malities in heart failure. J Card Fail
2008; 14: 695–702.
2. Siegel JL, Miller A, Brown LK, DeLuca A,
Teirstein AS. Pulmonary diffusing capac-
ity in left ventricular dysfunction. Chest
1990; 98: 550–553.
3. Griffo R, Spanevello A, Temporelli PL,
Faggiano P, Carone M, Magni G,
Ambrosino N, Tavazzi L. Frequent
coexistence of chronic heart failure
and chronic obstructive pulmonary
disease in respiratory and cardiac out-
patients: evidence from SUSPIRIUM, a
multicentre Italian survey. Eur J
Prev Cardiol SAGE PublicationsSage
UK: London, England 2017; 24:
567–576.
4. Hawkins NM, Petrie MC, Jhund PS,
Chalmers GW, Dunn FG, McMurray JJ.
Heart failure and chronic obstructive
pulmonary disease: diagnostic pitfalls
and epidemiology. Eur J Heart Fail
2009; 11: 130–139.
5. Canepa M, Temporelli PL, Rossi A, Rossi
A, Gonzini L, Nicolosi GL, Staszewsky L,
Marchioli R, Pietro MA, Tavazzi L. Prev-
alence and prognostic impact of chronic
obstructive pulmonary disease in pa-
tients with chronic heart failure: data
from the GISSI-HF trial. Cardiology
2016; 136: 128–137.
6. Olson TP, Beck KC, Johnson BD. Pulmo-
nary function changes associated with
cardiomegaly in chronic heart failure.
J Card Fail 2007; 13: 100–107.
7. Wright RS, Levine MS, Bellamy PE,
Simmons MS, Batra P, Stevenson LW,
Walden JA, Laks H, Tashkin DP. Ventila-
tory and diffusion abnormalities in
potential heart transplant recipients.
Chest 1990; 98: 816–820.
8. Puri S, Baker BL, Oakley CM, Hughes
JM, Cleland JG. Increased alveolar/
capillary membrane resistance to gas
transfer in patients with chronic heart
failure. Br Heart J 1994; 72: 140–144.
9. Daganou M, Dimopoulou I, Alivizatos
PA, Tzelepis GE. Pulmonary function
and respiratory muscle strength in
chronic heart failure: comparison be-
tween ischaemic and idiopathic dilated
cardiomyopathy. Heart 1999; 81:
618–620.
10. Guazzi M. Alveolar–capillary membrane
dysfunction in heart failure: evidence of
a pathophysiologic role. Chest 2003;
124: 1090–1102.
11. Faggiano P, D’Aloia A, Gualeni A,
Giordano A. Relative contribution of
resting haemodynamic proﬁle and lung
function to exercise tolerance in male
patients with chronic heart failure.
Heart 2001; 85: 179–184.
12. Olson TP, Denzer DL, Sinnett WL, Wil-
son T, Johnson BD. Prognostic value of
resting pulmonary function in heart fail-
ure. Clin Med Insights Circ Respir Pulm
Med 2013; 7: 35–43.
13. Gerges C, Gerges M, Lang MB, Zhang Y,
Jakowitsch J, Probst P, Maurer G,
Lang IM. Diastolic pulmonary vascular
pressure gradient: a predictor of
prognosis in ‘out-of-proportion’ pulmo-
nary hypertension. Chest 2013; 143:
758–766.
14. Quanjer PH, Tammeling GJ, Cotes JE,
Pedersen OF, Peslin R, Yernault JC. Lung
volumes and forced ventilatory ﬂows.
Eur Respir J Eur Res Soc 1993; 6: 5–40.
15. Cotes JE, Chinn DJ, Quanjer PH, Roca J,
Yernault JC. Standardization of the
measurement of transfer factor (diffus-
ing capacity). Report Working Party
Standardization of Lung Function Tests,
European Community for Steel and
Coal. Ofﬁcial Statement of the European
Respiratory Society. Eur Respir J Suppl
1993; 16: 41–52.
16. Magnussen H, Canepa M, Zambito PE,
Brusasco V, Meinertz T, Rosenkranz S.
What can we learn from pulmonary
function testing in heart failure? Eur J
Heart Fail 2017; 19: 1222–1229.
17. Puri S, Baker BL, Dutka DP, Oakley CM,
Hughes JM, Cleland JG. Reduced
alveolar–capillary membrane diffusing
capacity in chronic heart failure. Its
pathophysiological relevance and rela-
tionship to exercise performance. Circu-
lation 1995; 91: 2769–2774.
18. Assayag P, Benamer H, Aubry P, De PC,
Brochet E, Besse S, Camus F. Alteration
of the alveolar–capillary membrane
diffusing capacity in chronic left heart
disease. Am J Cardiol 1998; 82:
459–464.
19. Miniati M, Monti S, Bottai M, Pavlickova
I, Passino C, Emdin M, Poletti R. Prog-
nostic value of alveolar volume in
systolic heart failure: a prospective ob-
servational study. BMC Pulm Med 2013;
13: 69.
20. Guazzi M, Agostoni P, Bussotti M,
Guazzi MD. Impeded alveolar–capillary
gas transfer with saline infusion in
heart failure. Hypertension 1999; 34:
1202–1207.
21. Puri S, Dutka DP, Baker BL, Hughes JM,
Cleland JG. Acute saline infusion reduces
386 T. Deis et al.
ESC Heart Failure 2019; 6: 379–387
DOI: 10.1002/ehf2.12401
alveolar–capillary membrane conduc-
tance and increases airﬂow obstruction
in patients with left ventricular dysfunc-
tion. Circulation 1999; 99: 1190–1196.
22. Mettauer B, Lampert E, Charloux A,
Zhao QM, Epailly E, Oswald M, Frans
A, Piquard F, Lonsdorfer J. Lung mem-
brane diffusing capacity, heart failure,
and heart transplantation. Am J Cardiol
1999; 83: 62–67.
23. Ravenscraft SA, Gross CR, Kubo SH,
Olivari MT, Shumway SJ, Bolman RM,
Hertz MI. Pulmonary function after
successful heart transplantation; one
year follow-up. Chest 1993; 103:
54–58.
24. Hoeper MM, Meyer K, Rademacher J,
Fuge J, Welte T, Olsson KM. Diffusion
capacity and mortality in patients with
pulmonary hypertension due to heart
failure with preserved ejection fraction.
JACC Hear Fail 2016; 4: 441–449.
25. Huang W, Resch S, Oliveira RK, Cockrill
BA, Systrom DM, Waxman AB. Invasive
cardiopulmonary exercise testing in the
evaluation of unexplained dyspnea: in-
sights from a multidisciplinary dyspnea
center. Eur J Prev Cardiol 2017; 24:
1190–1199.
Lung diffusion capacity in advanced HF 387
ESC Heart Failure 2019; 6: 379–387
DOI: 10.1002/ehf2.12401
